B+
Bull case
25%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
ZVRA
Zevra TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q2 net revenue rose 53% year over year to $39.7 million, led by MIPLYFFA, and Zevra reported $260.2 million of cash, equivalents and investments at June 30. Sustained uptake and a favorable EU reversal could improve the outlook.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.6.
What can break
Commercial execution, R&D spending and potential dilution remain relevant despite the June cash balance. [#SEC-8K-2026-08-05]
Momentum
35
Value
67
Sentiment
66
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $10.50 · Bull $15.00 · Bear $6.00Analysis 2026-10-26; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-26 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $25.00
Why
Momentum35 · Δ7d -6.6
Value67 · Δ7d +0.6
Sentiment66 · Δ7d -0.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta +0.6.
Contradictions & invalidation
- • Commercial execution, R&D spending and potential dilution remain relevant despite the June cash balance. [#SEC-8K-2026-08-05]
- • DiSCOVER's event-driven design and low confirmed-event count make readout timing uncertain. [#SEC-8K-2026-08-05]
- • Fourteen new Q2 prescription enrollment forms leave uptake persistence uncertain.
Catalyst clock
2026-11-03
November 3 results test MIPLYFFA uptake
Lead driver: Value · See fundamentals
Momentum
35
8% active weight
Current posture
7d trendSoftening
Δ7d
-6.6
Δ21d
-10.4
Value
67
47% active weight
Current posture
7d trendFlat
Δ7d
+0.6
Δ21d
+0.5
Sentiment
66
45% active weight
Current posture
7d trendFlat
Δ7d
-0.6
Δ21d
-14.3
Why this grade
Composite grade A. Momentum 35.4 / Value 67.4 / Sentiment 65.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-26. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$10.50
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$565.93M
Beta
0.99
Shares Out
59.38M
P/E (TTM)
14.1
P/S (TTM)
5.56
P/FCF (TTM) · Derived
17.58
Rev YoY
+53.3%
EPS YoY
-90.0%
Gross Margin
+94.5%
Op Margin
+28.7%
Net Debt
-$127.81M
Current Ratio
5.17
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data